Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

L-Carnitine and Reduced Migraine Severity

Doses used in studies

mg/day: 500 (median 500, IQR 500–500) — 2 studies

Time to effect

Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 2 of 2 studies

2 of 2 papers

The effects of concurrent alpha-linolenic acid, L-carnitine supplementation on clinical symptoms, mental health, and quality of life in women with migraine: a randomized, triple-blind, placebo-controlled trial.
- 2025-03-13
- RCT · n = 80
- Nutrition journal 24(1)
- - Sahar Golpour-Hamedani
  - Mohammad Bagherniya
  - Fariborz Khorvash
  - Awat Feizi
  - Manoj Sharma
  - Gholamreza Askari
- PubMed: 40082970
- DOI: 10.1186/s12937-025-01107-7
7 Insights on
- Reduced Migraine Severity
- High evidence
- Clinical
severity (-1.6; 95% CI (-2.05, -1.15) vs - 0.44; 95% CI (-0.91, 0.02), P = 0.001)
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
500 mg/day
Investigating the effects of co-supplementation with alpha-linolenic acid and L-carnitine on inflammatory status, oxidative stress, clinical symptoms, mental health and quality of life in women with migraine: a protocol for a randomized, triple-blind, placebo-controlled trial.
- 2024-10-08
- RCT · n = 80
- Trials 25(1)
- - Sahar Golpour-Hamedani
  - Mohammad Bagherniy
  - Fariborz Khorvash
  - Awat Feizi
  - Manoj Sharma
  - Gholamreza Askari
- PubMed: 39380085
- DOI: 10.1186/s13063-024-08500-3
11 Insights on
- Reduced Migraine Severity
- High evidence
- Clinical
The primary outcomes include changes in clinical symptoms of migraine, including frequency, severity, and duration of attacks
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
500 mg/day